ArticleInternational journal of retina and vitreous2026
Off-label intravitreal eculizumab for geographic atrophy: report of the first two cases.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the feasibility and short-term safety of off-label intravitreal eculizumab as a complement-inhibition strategy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), based on two clinical cases. CASE REPORTS: Two pseudophakic patients with progressive bilateral visual decline presented with GA and drusen in both eyes. Because this represents a novel, off-label therapeutic approach, intravitreal eculizumab was administered first in the worse-seeing eye in both cases, which also exhibited more advanced atrophic involvement. The treatment was selected as a potentially more accessible alternative to pegcetacoplan or avacincaptad pegol, which remain unavailable in Brazil. At fourmonth follow-up, no ocular toxicity was observed. There was no reduction in visual acuity in the treated eyes; in Case 1, BCVA improved from 20/400 to 20/200, while Case 2 maintained baseline acuity. Full-field electroretinography performed at baseline and at month 1 demonstrated preserved responses without reduction in B-wave amplitude, and multifocal electroretinography showed stable response densities with no amplitude loss.After functional assessment, structural multimodal imaging also showed no evidence of toxicity. Optical coherence tomography (OCT) revealed stable GA-related outer retinal atrophy without inner retinal changes, intra- or subretinal fluid, or any signs of acute retinal injury. Fundus autofluorescence and OCT angiography remained unchanged, with no findings of ocular inflammation, vascular compromise, or early acceleration of GA progression.
conclusionsIntravitreal eculizumab was feasible and demonstrated short-term safety in these two cases, with preserved visual function and no electrophysiological or structural evidence of toxicity. While biologically plausible as a C5-inhibition strategy, its therapeutic benefit remains unproven. Larger, controlled studies with extended follow-up are required to clarify long-term safety and efficacy in geographic atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.